Phase I study of indibulin in combination with erlotinib in advanced solid tumors.
Latest Information Update: 11 Feb 2022
At a glance
- Drugs Indibulin (Primary) ; Erlotinib
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Alaunos Therapeutics
- 18 Jul 2012 Planned end date changed from 1 Jan 2009 to 1 Jun 2013 as reported by ClinicalTrials.gov.
- 18 Jul 2012 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
- 01 Jul 2009 Actual end date (Feb 2009) added as reported by ClinicalTrials.gov.